Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue
NCT01480284
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
166
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatitis B, Chronic
Interventions
DRUG:
GSK548470 300 mg tablet
DRUG:
ETV 0.5 mg capsule
Sponsor
GlaxoSmithKline